Paul Capital Partners has promoted Ken Macleod to partner for the Paul Capital Healthcare funds in the firm’s London office.
Macleod has been with the firm for four years and is responsible for sourcing, evaluating and negotiating healthcare investments in Europe and Asia.
Prior to joining Paul Capital, Macleod was a venture partner at Schroder Ventures Life Sciences. He also has 15 years of operational experience in the pharmaceutical and biotechnology industries.
Paul Capital Healthcare has about $1.4 billion (€897 million) in committed capital for investment in the pharmaceutical, biotechnology and medical device industries. The group has committed $940 million to 37 healthcare investments including $395 million invested in 14 transactions in Europe and Asia.
The firm most recently invested up to $28 million in UK-based urological disorder treatment company Plethora Solutions and €18.4 million in UK-based Vernalis in relation to a migraine treatment product.
Paul Capital Healthcare closed its first fund on approximately $300 million in 2000 and closed its second fund on about $650 million in 2003. Fund II has issued an additional $450 million of debt in three asset-backed note offerings.
The firm focusses on commercial stage companies and products, investing in the form of royalties, revenue interest, debt and equity.
In addition to healthcare investing, the firm has secondary private equity and venture capital fund of funds investment platforms.